DDInter704 DDInter737
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fingolimod
Everolimus {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Cardiac arrest {u} (Side Effect) is caused by {v} (Compound) Fingolimod
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fingolimod
Everolimus {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Cardiac arrest {u} (Side Effect) is caused by {v} (Compound) Edrophonium
Edrophonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Everolimus {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fingolimod
Everolimus {u} (Compound) causes {v} (Side Effect) Lymphoproliferative disorder
Lymphoproliferative disorder {u} (Side Effect) is caused by {v} (Compound) Methotrexate
Methotrexate {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Everolimus {u} (Compound) upregulates {v} (Gene) OSBP
OSBP {u} (Gene) is downregulated by {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Fingolimod
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fingolimod
Everolimus {u} (Compound) upregulates {v} (Gene) CBLB
CBLB {u} (Gene) is associated with {v} (Disease) multiple sclerosis
multiple sclerosis {u} (Disease) is treated by {v} (Compound) Fingolimod
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Everolimus (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Fingolimod
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Everolimus (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Edrophonium (Compound) and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Everolimus (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Everolimus (Compound) causes Lymphoproliferative disorder (Side Effect) and Lymphoproliferative disorder (Side Effect) is caused by Methotrexate (Compound) and Methotrexate may lead to a major life threatening interaction when taken with Fingolimod
Everolimus (Compound) upregulates OSBP (Gene) and OSBP (Gene) is downregulated by multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound)
Everolimus (Compound) upregulates CBLB (Gene) and CBLB (Gene) is associated with multiple sclerosis (Disease) and multiple sclerosis (Disease) is treated by Fingolimod (Compound)